Medication Name

Hydrochlorothiazide

Therapeutic Class

Thiazide Diuretic

Primary Indications

Hypertension, Edema

Mechanism Of Action

Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water, thereby reducing blood pressure.

Dosage Forms

Tablets, Capsules

Available Strengths

12.5 mg, 25 mg, 50 mg

Administration Route

Oral

Dosing Frequency

Once daily

Maximum Dosage

100 mg per day

Use In Combination

Often used with other antihypertensives like ACE inhibitors, beta-blockers, or ARBs.

Drug-Drug Interactions

NSAIDs may reduce diuretic effectiveness. Lithium clearance is reduced, increasing toxicity risk. Concurrent use with corticosteroids can cause hypokalemia.

Contraindications

Anuria, Hypersensitivity to Sulfonamide-Derived Drugs

Precautionary Conditions

Severe Renal Impairment, Liver Disease

Possible Side Effects

Hypokalemia, Hyperglycemia, Hyperuricemia, Photosensitivity

Lab Monitoring

Serum Electrolytes, Renal Function, Blood Glucose

Storage Conditions

Store at room temperature, protect from light and moisture.

Overdose Management

Symptomatic and Supportive Treatment

Non-Indicated Uses

Not indicated for initial treatment of malignant hypertension.

Pediatric Use

Safety and Efficacy not established in children under 6 months.

Geriatric Use

Monitor for hypokalemia and hypotension due to increased sensitivity.

Pregnancy Category

Category B: Animal reproduction studies have not demonstrated risk.

Lactation Considerations

Small amounts excreted in breast milk; use caution.

Patient Counseling Information

Advise on the risk of photosensitivity, emphasizing the need to use sunscreen or wear protective clothing.

Discontinuation Guidance

Do not abruptly discontinue without consulting a healthcare provider.

Manufacturing Companies

Manufactured by various pharmaceutical companies such as Mylan, Sandoz, and Teva.

Regulatory Status

FDA Approved

Bioavailability

Intermediate

Pharmacokinetics

Onset of action occurs in 2 hours, with peak effect at 4 to 6 hours. Half-life ranges between 6 to 15 hours.

Effect On Mental State

No impact reported on mental alertness or coordination.

Guideline Recommendations

Included in most guidelines as a first-line treatment for hypertension.

Diabetes Considerations

May exacerbate hyperglycemic episodes in diabetic patients.

Bone Density Effects

Long-term use may be associated with decreased bone mineral density.

Fluid Retention

Effectively reduces fluid retention in conditions like congestive heart failure.

Marketing Approval Date

First approved in 1959 for medical use.

Alternative Names

HCTZ, Hydrodiuril, Esidrix

Specific Populations

Adjust dosing in renal impairment, with careful monitoring for efficacy and toxicity.

Cost Considerations

Generally inexpensive, often included in generic drug programs.

Comorbidity Management

Useful in multifactorial therapeutic regimens targeting both hypertension and heart failure.

Patient Adherence

Oral administration once daily enhances patient adherence.

Alternative Therapies

Loop diuretics and potassium-sparing diuretics can be considered based on clinical indications.

Impact On Cholesterol

May cause a slight rise in cholesterol levels, requiring monitoring.

Electrolyte Imbalances

Monitor closely for hyponatremia and hypokalemia during therapy.

Dietary Considerations

Advise on maintaining a balanced diet rich in potassium sources to counteract hypokalemia.

Physical Exercise

Encourage physical activity, but caution regarding potential dehydration and electrolyte imbalance.

Long-Term Effectiveness

Remains effective for long-term management of hypertension and edema with appropriate monitoring.

Renal Function

Periodic assessment of renal function is essential to avoid complications.

Patient Education

Inform patients about the importance of adherence to therapy and regular follow-ups.